Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 1, 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital: 5,381,149,079 Ordinary Shares of 25 pence each (as of March 29, 2019).
- Treasury Shares: 393,505,950 Ordinary Shares.
- Total Voting Rights: 4,987,643,129.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data or discussion of changes in capital structure is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share counts intended to assist shareholders in calculating notification thresholds under FCA rules.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,987,643,129) to determine if disclosure thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (393,505,950) when calculating the denominator for ownership percentage.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.